Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in combination with PEG-interferon alpha 2a in patients with chronic HBV/HDV co-infection - Wedemeyer, H; Schoneweis, K; Bogomolov, PO (J Hepatol, 2019)
et al.